Cabometyx (Cabozantinib-S-Malate): Uses, Side Effects & Warnings

• Cabometyx is an oral kinase inhibitor approved for specific advanced cancers, including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.
• It works by targeting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastasis.
• Common side effects often include diarrhea, fatigue, nausea, and hand-foot syndrome, while serious risks can involve hemorrhage, gastrointestinal perforation, and hypertension.
• Strict adherence to prescribed dosage and close monitoring by a healthcare provider are crucial for managing side effects and optimizing treatment outcomes.
• Patients should report any new or worsening symptoms promptly to their doctor and be aware of potential drug interactions.

What is Cabometyx (Cabozantinib-S-Malate) Used For?

Cabometyx (Cabozantinib-S-Malate) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that plays a crucial role in oncology. It is designed to block the activity of several RTKs, including MET, VEGFR2, AXL, and RET, which are often overactive in various cancers and contribute to tumor growth, angiogenesis (formation of new blood vessels that feed tumors), and metastasis (spread of cancer cells). This targeted approach helps to inhibit the proliferation of cancer cells and impede their ability to spread throughout the body.

The primary Cabometyx uses and side effects are well-documented across several indications. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy, and also as a first-line treatment for advanced RCC. Furthermore, it is indicated for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, and for differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and is radioactive iodine-refractory.

Clinical trials have demonstrated the efficacy of Cabometyx in these advanced cancer settings. For instance, in a study published in The New England Journal of Medicine, Cabometyx significantly improved progression-free survival and overall survival in patients with advanced RCC compared to everolimus. Similarly, for HCC, a pivotal trial showed a significant improvement in overall survival for patients treated with Cabometyx compared to placebo. These findings underscore its importance as a therapeutic option, extending the lives of patients with these challenging cancers.

Cabometyx (Cabozantinib-S-Malate) Side Effects and Warnings

Understanding the potential side effects of Cabozantinib-S-Malate is essential for patients and healthcare providers to manage treatment effectively and safely. Like all potent medications, Cabometyx can cause a range of adverse reactions, some of which can be serious. Common side effects often include gastrointestinal issues such as diarrhea, nausea, vomiting, and constipation. Patients may also experience fatigue, decreased appetite, weight loss, and changes in taste. Skin reactions, particularly palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), characterized by redness, swelling, and pain on the palms and soles, are also frequently reported.

Beyond the common adverse events, there are significant Cabozantinib-S-Malate warnings that require careful monitoring. These include the risk of hemorrhage, which can be severe and even fatal, and gastrointestinal perforation or fistula formation. Hypertension (high blood pressure) is another serious concern, often requiring management with antihypertensive medications. Patients may also experience arterial and venous thromboembolic events, such as blood clots, and proteinuria (protein in the urine). Liver enzyme elevations, osteonecrosis of the jaw, and impaired wound healing are also potential risks. Due to these serious risks, patients undergoing treatment with Cabometyx must be closely monitored by their healthcare team, with regular assessments of blood pressure, liver function, and other relevant parameters.

Patients should be vigilant in reporting any new or worsening symptoms to their doctor immediately. Early detection and management of side effects can often prevent them from becoming more severe. For example, persistent diarrhea can lead to dehydration and electrolyte imbalances if not addressed promptly. Similarly, uncontrolled hypertension can increase the risk of cardiovascular events. The decision to continue or modify treatment with Cabometyx often involves a careful balance between its therapeutic benefits and the management of its associated risks, tailored to each patient’s individual health status and tolerance.

Managing Common Side Effects

Proactive management strategies can help mitigate many of the common side effects associated with Cabometyx. For instance, anti-diarrheal medications can be prescribed to control diarrhea, while antiemetics can help with nausea and vomiting. Maintaining good hydration and nutrition is also crucial. For hand-foot syndrome, emollients, pain relievers, and dose adjustments may be necessary. Patients are often advised to avoid activities that put pressure on their hands and feet and to wear comfortable footwear. Regular communication with the healthcare team allows for timely interventions and adjustments to the treatment plan, ensuring that side effects are managed effectively without compromising the overall therapeutic goal.

Important Safety Precautions

Several safety precautions are paramount when taking Cabometyx. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose, as Cabometyx can cause fetal harm. Breastfeeding is not recommended during treatment and for 4 months after the last dose. Patients should inform their doctor about all other medications they are taking, including over-the-counter drugs, herbal supplements, and vitamins, as drug interactions can occur. For example, strong CYP3A4 inhibitors (like ketoconazole) can increase Cabometyx exposure, while strong CYP3A4 inducers (like rifampin) can decrease it, potentially affecting efficacy or increasing toxicity. Dose adjustments may be necessary based on these interactions.

Cabometyx Dosage, Interactions, and Patient Information

The appropriate Cabometyx dosage and warnings are critical for optimizing treatment outcomes while minimizing adverse effects. Cabometyx is available as tablets and is typically taken once daily, with or without food. The exact dose depends on the specific cancer being treated and the patient’s individual response and tolerance. For advanced renal cell carcinoma and hepatocellular carcinoma, the recommended starting dose is usually 60 mg orally once daily. For differentiated thyroid cancer, a lower starting dose of 40 mg orally once daily is often prescribed. It is crucial for patients to take the medication exactly as prescribed by their healthcare provider and not to alter the dose or stop treatment without medical advice.

Cabometyx patient information emphasizes the importance of consistent administration. If a dose is missed, patients should not take a double dose to make up for it. Instead, they should take the next scheduled dose at the regular time. If vomiting occurs after taking a dose, patients should not take an additional dose but continue with their next scheduled dose. Proper storage is also important; Cabometyx tablets should be stored at room temperature, away from moisture and heat. Patients should always keep the medication out of reach of children and pets. Adherence to these guidelines helps maintain consistent drug levels in the body, which is essential for the medication’s efficacy.

Drug interactions are a significant consideration when prescribing Cabometyx. As mentioned, strong inhibitors or inducers of CYP3A4 can affect cabozantinib levels. For instance, co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice) can increase cabozantinib exposure, potentially leading to increased toxicity. Conversely, co-administration with strong CYP3A4 inducers (e.g., phenytoin, St. John’s wort) can decrease cabozantinib exposure, potentially reducing its effectiveness. Healthcare providers must review all concomitant medications to identify and manage potential interactions, often requiring dose adjustments of Cabometyx or alternative medications. Other interactions may include proton pump inhibitors (PPIs) or H2-receptor antagonists, which can alter gastric pH and potentially affect cabozantinib absorption, though the clinical significance of these interactions is generally considered minimal.

Frequently Asked Questions About Cabometyx

How should Cabometyx be taken?

Cabometyx is taken orally, typically once daily. It can be taken with or without food, but it is important to avoid food for at least 2 hours before and 1 hour after taking the dose if you are consuming grapefruit or grapefruit juice, as these can interfere with the medication. Always follow your doctor’s specific instructions regarding dosage and administration. Do not crush, chew, or split the tablets; swallow them whole. Consistency in taking the medication at the same time each day is recommended.

What are the most common side effects of Cabometyx?

The most common side effects of Cabometyx include diarrhea, fatigue, nausea, decreased appetite, vomiting, weight loss, and palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome). Patients may also experience hypertension (high blood pressure), abdominal pain, and changes in liver function tests. It is crucial to report any persistent or severe side effects to your healthcare provider, as dose adjustments or supportive care may be necessary to manage these symptoms effectively and safely.

Who should not take Cabometyx?

Cabometyx may not be suitable for everyone. Individuals with certain pre-existing conditions, such as uncontrolled hypertension, recent history of hemorrhage, or gastrointestinal perforation, may be at higher risk for serious complications. Pregnant or breastfeeding women should avoid Cabometyx due to potential harm to the fetus or infant. Patients with severe liver impairment may require dose adjustments. Always discuss your complete medical history and all current medications with your doctor to determine if Cabometyx is the right treatment option for you.